Executive at Exponent (EXPO) receives 2,970 restricted stock units

Rhea-AI Filing Summary

Reiss Richard reported acquisition or exercise transactions in this Form 4 filing.

Exponent Inc reported that Group Vice President Richard Reiss received a grant of 2,970 restricted stock units on March 13, 2026. These RSUs represent the right to receive 2,970 shares of common stock on a 1-for-1 basis, as noted in the footnotes. Following this award, his reported derivative holdings in these RSUs total 2,970 units, reflecting routine equity-based compensation rather than any open-market buying or selling of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reiss Richard

Role Group Vice President

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	2,970	$0.00	--

Holdings After Transaction: Restricted Stock Units — 2,970 shares (Direct)

Footnotes (1)

1. 1-for-1. Not applicable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reiss Richard

(Last) (First) (Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		A		2,970		03/13/2030	03/13/2030	Common Stock	2,970	(2)	2,970	D

Explanation of Responses:

1. 1-for-1.

2. Not applicable.

	By: Wendy Whitehouse For: Richard Reiss	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Exponent (EXPO) disclose for Richard Reiss?

Exponent disclosed that Group Vice President Richard Reiss received 2,970 restricted stock units as an equity award. The grant is coded as an acquisition (grant or award) rather than an open-market purchase or sale, reflecting routine stock-based executive compensation.

How many restricted stock units did Richard Reiss receive at Exponent (EXPO)?

Richard Reiss received 2,970 restricted stock units tied to Exponent common stock. Each unit represents the right to receive one share, according to a 1-for-1 ratio noted in the footnotes, giving him exposure to 2,970 potential common shares.

Was the Exponent (EXPO) Form 4 transaction a stock purchase or sale?

The Form 4 transaction was not a market purchase or sale; it was an award. Richard Reiss acquired 2,970 restricted stock units coded as a grant, meaning the company granted these units as compensation rather than him buying or selling shares in the open market.

What is the share conversion ratio for Richard Reiss’s Exponent (EXPO) RSUs?

The restricted stock units convert to common stock on a 1-for-1 basis. Footnotes specify “1-for-1,” and the filing shows 2,970 underlying common shares for 2,970 RSUs, so each unit corresponds to one share if and when settled.

What are the key dates associated with Richard Reiss’s Exponent (EXPO) RSU grant?

The RSU grant date is listed as March 13, 2026, with both exercise and expiration dates recorded as March 13, 2030. These dates frame the life of the award, although specific vesting conditions are not detailed in the provided information.